Ingram Micro Cloud Publishes Cloud Technology: The State of MSPs Report Aimed at Guiding Reseller Success
29.3.2022 16:00:00 EEST | Business Wire | Press release
Ingram Micro Cloud, operator of the world’s largest cloud marketplace for the channel, announced on March 3rd the creation and release of its annual report examining prescient trends affecting Managed Service Providers (MSPs) and technology resellers. Cloud Technology: The State of MSPs Report analyzes key barriers and weaknesses that need to be addressed by MSPs in order to maximize on new and forecasted opportunities within the channel.
Cloud Technology: The State of MSPs Report is available for download here.
Drawing on the insights from over 600 MSPs acquired by Ingram Micro Cloud and global technology market research experts Vanson Bourne during an era of the greatest transformational shift in the history of the channel, the report provides revelations meant to benefit resellers and MSPs directly as they learn to navigate new business landscapes. Among its findings, the report recommends channel partners evolve to become strategic advisors to their customers; identify the most popular services provided by MSPs, including managed security and cloud services; and ensure they are in the best position to take advantage of the ever-increasing drive towards digitalization.
“From interviewing over 600 MSPs, it’s remarkable to see how 90% of service providers have seen client demand for managed services grow in the past 12 months, and close to two in three individuals surveyed say a lot of improvement is needed if their organization is going to be able to adapt to future opportunities,” said Craig Weir, executive director, global SaaS portfolio at Ingram Micro Cloud.
The report examines industry developments and MSP opportunities in the channel. These insights include:
- How MSPs are handling surging client demand and dramatic levels of growth.
- The top reasons why organizations look to outsource their IT operations.
- The most common managed services requested by clients.
- What MSPs believe to be the greatest opportunities in the marketplace right now.
- The challenges most likely to keep senior decision makers up at night.
Weir continues, “Today, I believe most MSPs are stuck in a digital impasse. Many MSPs are at an inflection point of knowing where they should go, but they just don’t know how to get there or even how to start. As we comb through the data, it’s clear to us some MSPs have solved this puzzle. They have enabled scale, they have found ways to accelerate growth, both of which have increased topline revenue; all while expanding recurring revenue streams to improve their bottom line. We see this today in what we call the Modern MSP.”
In closing, global managed services market will rise from $243 billion in 2021 to $557 billion in 2028, at a CAGR of 12.6%.1 Over the past 12 months, the top 3 services that generated the most revenue were: Cloud Services (SaaS, IaaS, PaaS) (22%), Managed Security (19%), and Internal IT Department (17%). All of this is indicative of the opportunity for MSPs to take notice and develop a stronger cloud business plan for the year and beyond. One thing is clear: it’s a great time to be an MSP.
For more information on the Cloud Technology: The State of MSPs Report and how Ingram Micro Cloud is helping partners leverage the research findings, visit here.
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problem solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers, and managed service providers by offering More as a Service. Detailed information is available at www.ingrammicrocloud.com.
Sources:
1. Managed Services Market Size, Share & COVID-19 Impact Analysis, By Services (Voice Service, Non-Voice Service, and IT Managed Service), By Function (Finance & Accounting (F & A), Marketing, Procurement, Supply Chain, Human Resource, and Information Technology (IT)), By End-user (Medical, Financial, Government, Audit & Consulting, Corporate, Telecom, and Insurance & Reinsurance), and Regional Forecast, 2021-2028,” Fortune Business Insights, August 2021. https://www.fortunebusinessinsights.com/managed-services-market-102430
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005020/en/
Contact information
Megan Binkley
Ingram Micro Cloud
Megan.Binkley@ingrammicro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom